# Robert A Bonomo

# List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/3975696/robert-a-bonomo-publications-by-year.pdf

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

309	17,215	65	122
papers	citations	h-index	g-index
357 ext. papers	21,530 ext. citations	6.7 avg, IF	7.15 L-index

#	Paper	IF	Citations
309	Inhibiting Mycobacterium abscessus Cell Wall Synthesis: Using a Novel Diazabicyclooctane Lactamase Inhibitor To Augment Lactam Action <i>MBio</i> , <b>2022</b> , e0352921	7.8	2
308	and sp. inhibit osseointegration of orthopaedic implants Infection and Immunity, 2022, iai0066921	3.7	0
307	Accuracy of Direct Antimicrobial Susceptibility of Gram-Negative Bacteria from Positive Blood Cultures using MicroScan System and Value of Using Expert Rules for Lactam Agents  Antimicrobial Agents and Chemotherapy, 2022, aac0214821	5.9	O
306	Deciphering the evolution of metallo-flactamases: a journey from the test tube to the bacterial periplasm <i>Journal of Biological Chemistry</i> , <b>2022</b> , 101665	5.4	2
305	An Analysis of the Novel Fluorocycline TP-6076 Bound to Both the Ribosome and Multidrug Efflux Pump AdeJ from Acinetobacter baumannii <i>MBio</i> , <b>2022</b> , e0373221	7.8	1
304	Clinical challenges treating infections: an update JAC-Antimicrobial Resistance, 2022, 4, dlac040	2.9	5
303	Discovery of an Effective Small-Molecule Allosteric Inhibitor of New Delhi Metallo-Elactamase (NDM) ACS Infectious Diseases, 2022, 8, 811-824	5.5	1
302	Structural Characterization of the D179N and D179Y Variants of KPC-2 Lactamase: Loop Destabilization as a Mechanism of Resistance to Ceftazidime-Avibactam <i>Antimicrobial Agents and Chemotherapy</i> , <b>2022</b> , e0241421	5.9	1
301	Accessory Genomes Drive Independent Spread of Carbapenem-Resistant Klebsiella pneumoniae Clonal Groups 258 and 307 in Houston, TX <i>MBio</i> , <b>2022</b> , e0049722	7.8	2
300	Different Conformations Revealed by NMR Underlie Resistance to Ceftazidime/Avibactam and Susceptibility to Meropenem and Imipenem among D179Y Variants of KPC Lactamase  Antimicrobial Agents and Chemotherapy, 2022, e0212421	5.9	1
299	Human Serum Proteins and Susceptibility of to Cefiderocol: Role of Iron Transport <i>Biomedicines</i> , <b>2022</b> , 10,	4.8	2
298	Genomic heterogeneity underlies multidrug resistance in Pseudomonas aeruginosa: A population-level analysis beyond susceptibility testing <i>PLoS ONE</i> , <b>2022</b> , 17, e0265129	3.7	O
297	Carbapenem-Resistant Acinetobacter baumannii in U.S. Hospitals: Diversification of Circulating Lineages and Antimicrobial Resistance <i>MBio</i> , <b>2022</b> , e0275921	7.8	O
296	Consensus on Elactamase Nomenclature Antimicrobial Agents and Chemotherapy, 2022, e0033322	5.9	2
295	Imipenem/Relebactam Resistance in Clinical Isolates of Extensively Drug Resistant Pseudomonas aeruginosa: Inhibitor-Resistant Lactamases and Their Increasing Importance <i>Antimicrobial Agents and Chemotherapy</i> , <b>2022</b> , e0179021	5.9	
294	Carbapenemase-producing Enterobacterales in solid organ transplantation: Tip of the iceberg?. <i>Transplant Infectious Disease</i> , <b>2021</b> ,	2.7	0
293	European Society of clinical microbiology and infectious diseases (ESCMID) guidelines for the treatment of infections caused by Multidrug-resistant Gram-negative bacilli (endorsed by ESICM-European Society of intensive care Medicine) Clinical Microbiology and Infection, <b>2021</b> ,	9.5	27

#### (2021-2021)

292	Infectious Diseases Society of America Guidance on the Treatment of AmpC Elactamase-Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections. <i>Clinical Infectious Diseases</i> , <b>2021</b> ,	11.6	27
291	The BioWipe: a non-invasive method to detect intestinal carriage of multi-drug resistant gram-negative bacteria. <i>Journal of Chemotherapy</i> , <b>2021</b> , 1-3	2.3	1
290	Clinical outcomes and bacterial characteristics of carbapenem-resistant Klebsiella pneumoniae complex among patients from different global regions (CRACKLE-2): a prospective, multicentre, cohort study. <i>Lancet Infectious Diseases, The</i> , <b>2021</b> ,	25.5	9
289	Structural analysis of the boronic acid Elactamase inhibitor vaborbactam binding to Pseudomonas aeruginosa penicillin-binding protein 3. <i>PLoS ONE</i> , <b>2021</b> , 16, e0258359	3.7	2
288	Desirability of Outcome Ranking for the Management of Antimicrobial Therapy (DOOR MAT): A Framework for Assessing Antibiotic Selection Strategies in the Presence of Drug Resistance. <i>Clinical Infectious Diseases</i> , <b>2021</b> , 73, 344-350	11.6	6
287	Structural and Biochemical Characterization of the Novel CTX-M-151 Extended-Spectrum Lactamase and Its Inhibition by Avibactam. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2021</b> , 65,	5.9	1
286	Carbapenem Use Is Driving the Evolution of Imipenemase 1 Variants. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2021</b> , 65,	5.9	8
285	Allosteric communication in class A flactamases occurs via cooperative coupling of loop dynamics. <i>ELife</i> , <b>2021</b> , 10,	8.9	18
284	Risk Factors for and Mechanisms of listin esistance Among nterobacterales: Getting at the CORE of the Issue. <i>Open Forum Infectious Diseases</i> , <b>2021</b> , 8, ofab145	1	О
283	Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum Elactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa). Clinical	11.6	58
282	Human Pleural Fluid and Human Serum Albumin Modulate the Behavior of a Hypervirulent and Multidrug-Resistant (MDR) Representative Strain. <i>Pathogens</i> , <b>2021</b> , 10,	4.5	4
281	Monoclonal antibody requires immunomodulation for efficacy against Acinetobacter baumannii infection. <i>Journal of Infectious Diseases</i> , <b>2021</b> ,	7	1
280	Cryo-EM Determination of Eravacycline-Bound Structures of the Ribosome and the Multidrug Efflux Pump AdeJ of Acinetobacter baumannii. <i>MBio</i> , <b>2021</b> , 12, e0103121	7.8	6
279	Emergence of Resistance to Ceftazidime-Avibactam in a Pseudomonas aeruginosa Isolate Producing Derepressed in a Hollow-Fiber Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2021</b> , 65,	5.9	2
278	Detection of mcr-1 gene in a clinical Escherichia coli strain in North Carolina: first report. <i>Journal of Global Antimicrobial Resistance</i> , <b>2021</b> , 25, 154-156	3.4	1
277	"One-Two Punch": Synergistic Lactam Combinations for Mycobacterium abscessus and Target Redundancy in the Inhibition of Peptidoglycan Synthesis Enzymes. <i>Clinical Infectious Diseases</i> , <b>2021</b> , 73, 1532-1536	11.6	3
276	A comprehensive and contemporary "snapshot" of Elactamases in carbapenem resistant Acinetobacter baumannii. <i>Diagnostic Microbiology and Infectious Disease</i> , <b>2021</b> , 99, 115242	2.9	8
275	Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum Elactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa). Clinical	11.6	105

274	Natural variants modify Klebsiella pneumoniae carbapenemase (KPC) acyl-enzyme conformational dynamics to extend antibiotic resistance. <i>Journal of Biological Chemistry</i> , <b>2021</b> , 296, 100126	5.4	8
273	Cerebrospinal fluid (CSF) augments metabolism and virulence expression factors in Acinetobacter baumannii. <i>Scientific Reports</i> , <b>2021</b> , 11, 4737	4.9	7
272	Structural Characterization of Diazabicyclooctane flactam "Enhancers" in Complex with Penicillin-Binding Proteins PBP2 and PBP3 of Pseudomonas aeruginosa. <i>MBio</i> , <b>2021</b> , 12,	7.8	10
271	The urgent need for metallo-Elactamase inhibitors: an unattended global threat. <i>Lancet Infectious Diseases, The</i> , <b>2021</b> ,	25.5	23
270	Interaction of with Human Serum Albumin: Does the Host Determine the Outcome?. <i>Antibiotics</i> , <b>2021</b> , 10,	4.9	1
269	2-Mercaptomethyl Thiazolidines (MMTZs) Inhibit All Metallo-Lactamase Classes by Maintaining a Conserved Binding Mode. <i>ACS Infectious Diseases</i> , <b>2021</b> , 7, 2697-2706	5.5	8
268	A Elactam siderophore antibiotic effective against multidrug-resistant Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter spp. <i>European Journal of Medicinal Chemistry</i> , <b>2021</b> , 220, 113-	6.8 436	8
267	Specific Protein-Membrane Interactions Promote Packaging of Metallo-Lactamases into Outer Membrane Vesicles. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2021</b> , 65, e0050721	5.9	2
266	Monoclonal Antibody Therapy against. <i>Infection and Immunity</i> , <b>2021</b> , 89, e0016221	3.7	2
265	On the Offensive: the Role of Outer Membrane Vesicles in the Successful Dissemination of New Delhi Metallo-Eactamase (NDM-1). <i>MBio</i> , <b>2021</b> , 12, e0183621	7.8	4
264	The Role of Hydrophobic Nodes in the Dynamics of Class A Lactamases. <i>Frontiers in Microbiology</i> , <b>2021</b> , 12, 720991	5.7	2
263	Histone-like nucleoid-structuring protein (H-NS) regulatory role in antibiotic resistance in Acinetobacter baumannii. <i>Scientific Reports</i> , <b>2021</b> , 11, 18414	4.9	1
262	Interplay between Meropenem and Human Serum Albumin on Expression of Carbapenem Resistance Genes and Natural Competence in Acinetobacter baumannii. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2021</b> , 65, e0101921	5.9	4
261	2-Mercaptomethyl-thiazolidines use conserved aromatic-S interactions to achieve broad-range inhibition of metallo-Elactamases. <i>Chemical Science</i> , <b>2021</b> , 12, 2898-2908	9.4	7
260	OXA-23 FLactamase Overexpression in Acinetobacter baumannii Drives Physiological Changes Resulting in New Genetic Vulnerabilities. <i>MBio</i> , <b>2021</b> , e0313721	7.8	О
259	Drug-Resistant Tuberculosis: A Glance at Progress and Global Challenges. <i>Infectious Disease Clinics of North America</i> , <b>2020</b> , 34, 863-886	6.5	5
258	Structural Insights into Ceftobiprole Inhibition of Pseudomonas aeruginosa Penicillin-Binding Protein 3. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2020</b> , 64,	5.9	7
257	A Lactam Siderophore Antibiotic Effective against Multidrug-Resistant Gram-Negative Bacilli.  Journal of Medicinal Chemistry, <b>2020</b> , 63, 5990-6002	8.3	10

# (2020-2020)

256	Carbapenemases: Transforming into a Yet More Dangerous Menace. <i>Biomolecules</i> , <b>2020</b> , 10,	5.9	49
255	Insights into the l,d-Transpeptidases and d,d-Carboxypeptidase of Mycobacterium abscessus: Ceftaroline, Imipenem, and Novel Diazabicyclooctane Inhibitors. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2020</b> , 64,	5.9	8
254	⊞riazolylboronic Acids: A Promising Scaffold for Effective Inhibitors of KPCs. <i>ChemMedChem</i> , <b>2020</b> , 15, 1283-1288	3.7	1
253	Determining the optimal dosing of a novel combination regimen of ceftazidime/avibactam with aztreonam against NDM-1-producing Enterobacteriaceae using a hollow-fibre infection model. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2020</b> , 75, 2622-2632	5.1	12
252	1,2,3-Triazolylmethaneboronate: A Structure Activity Relationship Study of a Class of Lactamase Inhibitors against Cephalosporinase. <i>ACS Infectious Diseases</i> , <b>2020</b> , 6, 1965-1975	5.5	8
251	Cryo-electron Microscopy Structure of the Acinetobacter baumannii 70S Ribosome and Implications for New Antibiotic Development. <i>MBio</i> , <b>2020</b> , 11,	7.8	20
250	Structures of FOX-4 Cephamycinase in Complex with Transition-State Analog Inhibitors. <i>Biomolecules</i> , <b>2020</b> , 10,	5.9	2
249	Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2): a prospective cohort study. <i>Lancet Infectious Diseases, The</i> , <b>2020</b> , 20, 731-741	25.5	59
248	Colistin resistance in China: from outer membrane to One Health. <i>Lancet Infectious Diseases, The</i> , <b>2020</b> , 20, 1106-1108	25.5	2
247	Shedding of multidrug-resistant gram-negative bacilli by colonized patients during procedures and patient care activities. <i>American Journal of Infection Control</i> , <b>2020</b> , 48, 1336-1340	3.8	3
246	Core genome MLST and resistome analysis of Klebsiella pneumoniae using a clinically amenable workflow. <i>Diagnostic Microbiology and Infectious Disease</i> , <b>2020</b> , 97, 114996	2.9	4
245	Distinct Mechanisms of Dissemination of NDM-1 Metallo-Lactamase in Species in Argentina. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2020</b> , 64,	5.9	10
244	A Standard Numbering Scheme for Class C Lactamases. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2020</b> , 64,	5.9	25
243	Monitoring Ceftazidime-Avibactam and Aztreonam Concentrations in the Treatment of a Bloodstream Infection Caused by a Multidrug-Resistant Enterobacter sp. Carrying Both Klebsiella pneumoniae Carbapenemase-4 and New Delhi Metallo-Lactamase-1. Clinical Infectious Diseases,	11.6	34
242	Characterisation of ST25 NDM-1-producing Acinetobacter spp. strains leading the increase in NDM-1 emergence in Argentina. <i>Journal of Global Antimicrobial Resistance</i> , <b>2020</b> , 23, 108-110	3.4	3
241	Structural Insights into Inhibition of the Acinetobacter-Derived Cephalosporinase ADC-7 by Ceftazidime and Its Boronic Acid Transition State Analog. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2020</b> , 64,	5.9	2
240	Efflux pumps as interventions to control infection caused by drug-resistance bacteria. <i>Drug Discovery Today</i> , <b>2020</b> , 25, 2307-2316	8.8	8
239	Overview: The Ongoing Threat of Antimicrobial Resistance. <i>Infectious Disease Clinics of North America</i> , <b>2020</b> , 34, 649-658	6.5	11

238	Resistance to Novel Lactam-Lactamase Inhibitor Combinations: The "Price of Progress". <i>Infectious Disease Clinics of North America</i> , <b>2020</b> , 34, 773-819	6.5	30
237	AbGRI4, a novel antibiotic resistance island in multiply antibiotic-resistant Acinetobacter baumannii clinical isolates. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2020</b> , 75, 2760-2768	5.1	3
236	Genomic epidemiology of colistin-resistant Escherichia coli in China Lancet Microbe, The, 2020, 1, e51-	<b>≥52</b> .2	1
235	Predicting Elactam resistance using whole genome sequencing in Klebsiella pneumoniae: the challenge of Elactamase inhibitors. <i>Diagnostic Microbiology and Infectious Disease</i> , <b>2020</b> , 98, 115149	2.9	1
234	The H-NS Regulator Plays a Role in the Stress Induced by Carbapenemase Expression in Acinetobacter baumannii. <i>MSphere</i> , <b>2020</b> , 5,	5	4
233	The Pitt Bacteremia Score Predicts Mortality in Nonbacteremic Infections. <i>Clinical Infectious Diseases</i> , <b>2020</b> , 70, 1826-1833	11.6	29
232	Ceftolozane/Tazobactam vs Polymyxin or Aminoglycoside-based Regimens for the Treatment of Drug-resistant Pseudomonas aeruginosa. <i>Clinical Infectious Diseases</i> , <b>2020</b> , 71, 304-310	11.6	63
231	ARGONAUT II Study of the Activity of Plazomicin against Carbapenemase-Producing Klebsiella pneumoniae. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2020</b> , 64,	5.9	8
230	Evaluation of in vitro activity of ceftazidime/avibactam and ceftolozane/tazobactam against MDR Pseudomonas aeruginosa isolates from Qatar. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2019</b> , 74, 3497-3	5 <b>∂</b> :4	13
229	A Multi-Centered Case-Case-Control Study of Factors Associated With Klebsiella pneumoniae Carbapenemase-Producing Enterobacteriaceae Infections in Children and Young Adults. <i>Pediatric Infectious Disease Journal</i> , <b>2019</b> , 38, 490-495	3.4	6
228	Antibiotic collateral sensitivity is contingent on the repeatability of evolution. <i>Nature Communications</i> , <b>2019</b> , 10, 334	17.4	80
227	A Primer on AmpC Lactamases: Necessary Knowledge for an Increasingly Multidrug-resistant World. <i>Clinical Infectious Diseases</i> , <b>2019</b> , 69, 1446-1455	11.6	61
226	Targeting Multidrug-Resistant spp.: Sulbactam and the Diazabicyclooctenone Lactamase Inhibitor ETX2514 as a Novel Therapeutic Agent. <i>MBio</i> , <b>2019</b> , 10,	7.8	35
225	Rapid Replacement of Acinetobacter baumannii Strains Accompanied by Changes in Lipooligosaccharide Loci and Resistance Gene Repertoire. <i>MBio</i> , <b>2019</b> , 10,	7.8	16
224	Ceftazidime/Avibactam, Meropenem/Vaborbactam, or Both? Clinical and Formulary Considerations. <i>Clinical Infectious Diseases</i> , <b>2019</b> , 68, 519-524	11.6	88
223	Human Pleural Fluid Elicits Pyruvate and Phenylalanine Metabolism in to Enhance Cytotoxicity and Immune Evasion. <i>Frontiers in Microbiology</i> , <b>2019</b> , 10, 1581	5.7	12
222	Protein determinants of dissemination and host specificity of metallo-Elactamases. <i>Nature Communications</i> , <b>2019</b> , 10, 3617	17.4	29
221	Identification of Potential Virulence Factors in the Model Strain A118. <i>Frontiers in Microbiology</i> , <b>2019</b> , 10, 1599	5.7	19

#### (2018-2019)

220	External validation of the INCREMENT-CPE mortality score in a carbapenem-resistant Klebsiella pneumoniae bacteraemia cohort: the prognostic significance of colistin resistance. <i>International Journal of Antimicrobial Agents</i> , <b>2019</b> , 54, 442-448	14.3	6
219	Identification of four patients with colistin-resistant Escherichia coli containing the mobile colistin resistance mcr-1 gene from a single health system in Michigan. <i>Infection Control and Hospital Epidemiology</i> , <b>2019</b> , 40, 1059-1062	2	10
218	Natural history of Acinetobacter baumannii infection in mice. PLoS ONE, 2019, 14, e0219824	3.7	14
217	Structural Insights into the Inhibition of the Extended-Spectrum Lactamase PER-2 by Avibactam. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2019</b> , 63,	5.9	7
216	Population Structure, Molecular Epidemiology, and flactamase Diversity among Stenotrophomonas maltophilia Isolates in the United States. <i>MBio</i> , <b>2019</b> , 10,	7.8	26
215	Cryo-Electron Microscopy Structure of an Acinetobacter baumannii Multidrug Efflux Pump. <i>MBio</i> , <b>2019</b> , 10,	7.8	38
214	Cefiderocol: A Novel Siderophore Cephalosporin Defeating Carbapenem-resistant Pathogens. <i>Clinical Infectious Diseases</i> , <b>2019</b> , 69, S519-S520	11.6	22
213	Human pleural fluid triggers global changes in the transcriptional landscape of Acinetobacter baumannii as an adaptive response to stress. <i>Scientific Reports</i> , <b>2019</b> , 9, 17251	4.9	17
212	A Single Salt Bridge in VIM-20 Increases Protein Stability and Antibiotic Resistance under Low-Zinc Conditions. <i>MBio</i> , <b>2019</b> , 10,	7.8	13
211	H, C, and N backbone resonance assignments for KPC-2, a class A serine-Elactamase. <i>Biomolecular NMR Assignments</i> , <b>2019</b> , 13, 139-142	0.7	1
210	Interspecies DNA acquisition by a naturally competent Acinetobacter baumannii strain. <i>International Journal of Antimicrobial Agents</i> , <b>2019</b> , 53, 483-490	14.3	12
209	The Role of Trimethoprim/Sulfamethoxazole in the Treatment of Infections Caused by Carbapenem-Resistant. <i>Open Forum Infectious Diseases</i> , <b>2019</b> , 6, ofy351	1	10
208	The Reaction Mechanism of Metallo-Lactamases Is Tuned by the Conformation of an Active-Site Mobile Loop. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2019</b> , 63,	5.9	18
207	Human fluids alter DNA-acquisition in Acinetobacter baumannii. <i>Diagnostic Microbiology and Infectious Disease</i> , <b>2019</b> , 93, 183-187	2.9	10
206	New Treatment Options against Carbapenem-Resistant Infections. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2019</b> , 63,	5.9	112
205	ARGONAUT-I: Activity of Cefiderocol (S-649266), a Siderophore Cephalosporin, against Gram-Negative Bacteria, Including Carbapenem-Resistant Nonfermenters and with Defined Extended-Spectrum Lactamases and Carbapenemases. <i>Antimicrobial Agents and Chemotherapy</i> ,	5.9	57
204	Rapid Molecular Diagnostics to Inform Empiric Use of Ceftazidime/Avibactam and Ceftolozane/Tazobactam Against Pseudomonas aeruginosa: PRIMERS IV. <i>Clinical Infectious Diseases</i> , <b>2019</b> , 68, 1823-1830	11.6	27
203	It <b>R</b> too soon to pull the plug on antibiotic cycling. <i>Lancet Infectious Diseases, The</i> , <b>2018</b> , 18, 493	25.5	1

202	The Continuing Challenge of Metallo-Lactamase Inhibition: Mechanism Matters. <i>Trends in Pharmacological Sciences</i> , <b>2018</b> , 39, 635-647	13.2	83
201	Relebactam Is a Potent Inhibitor of the KPC-2 fLactamase and Restores Imipenem Susceptibility in KPC-Producing Enterobacteriaceae. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2018</b> , 62,	5.9	51
200	Strategic Approaches to Overcome Resistance against Gram-Negative Pathogens Using Lactamase Inhibitors and Lactam Enhancers: Activity of Three Novel Diazabicyclooctanes WCK 5153, Zidebactam (WCK 5107), and WCK 4234. <i>Journal of Medicinal Chemistry</i> , <b>2018</b> , 61, 4067-4086	8.3	77
199	DISC: Describing Infections of the Spine treated with Ceftaroline. <i>Journal of Global Antimicrobial Resistance</i> , <b>2018</b> , 13, 146-151	3.4	5
198	New Molecular Diagnostic Approaches to Bacterial Infections and Antibacterial Resistance. <i>Annual Review of Medicine</i> , <b>2018</b> , 69, 379-394	17.4	43
197	Evaluation of Sensititre Broth Microdilution Plate for determining the susceptibility of carbapenem-resistant Klebsiella pneumoniae to polymyxins. <i>Diagnostic Microbiology and Infectious Disease</i> , <b>2018</b> , 91, 89-92	2.9	6
196	Molecular characterisation of carbapenem-resistant Enterobacter cloacae complex in Colombia: bla and the Rehanging landscapeR <i>Journal of Global Antimicrobial Resistance</i> , <b>2018</b> , 13, 184-189	3.4	4
195	Therapies for multidrug resistant and extensively drug-resistant non-fermenting gram-negative bacteria causing nosocomial infections: a perilous journey toward Rnolecularly targeted Rtherapy. Expert Review of Anti-Infective Therapy, 2018, 16, 89-110	5.5	39
194	Carbapenemase-Producing Organisms: A Global Scourge. Clinical Infectious Diseases, 2018, 66, 1290-129	9 <b>7</b> 1.6	221
193	Probing the Interaction of Aspergillomarasmine A with Metallo-Elactamases NDM-1, VIM-2, and IMP-7. <i>ACS Infectious Diseases</i> , <b>2018</b> , 4, 135-145	5.5	37
192	Clinical Evolution of New Delhi Metallo-Lactamase (NDM) Optimizes Resistance under Zn(II) Deprivation. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2018</b> , 62,	5.9	43
191	Exploring Additional Dimensions of Complexity in Inhibitor Design for Serine Lactamases: Mechanistic and Intra- and Inter-molecular Chemistry Approaches. <i>Frontiers in Microbiology</i> , <b>2018</b> , 9, 62	2 <sup>5.7</sup>	25
190	A Noncanonical Metal Center Drives the Activity of the Sediminispirochaeta smaragdinae Metallo-Elactamase SPS-1. <i>Biochemistry</i> , <b>2018</b> , 57, 5218-5229	3.2	10
189	Activity of Ceftazidime-Avibactam against Carbapenem-Resistant and Hypervirulent Klebsiella pneumoniae Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2018</b> , 62,	5.9	15
188	Evolution of New Delhi metallo-Elactamase (NDM) in the clinic: Effects of NDM mutations on stability, zinc affinity, and mono-zinc activity. <i>Journal of Biological Chemistry</i> , <b>2018</b> , 293, 12606-12618	5.4	59
187	Multiple substitutions lead to increased loop flexibility and expanded specificity in carbapenemase OXA-239. <i>Biochemical Journal</i> , <b>2018</b> , 475, 273-288	3.8	13
186	Structure-Based Analysis of Boronic Acids as Inhibitors of Acinetobacter-Derived Cephalosporinase-7, a Unique Class C Lactamase. <i>ACS Infectious Diseases</i> , <b>2018</b> , 4, 325-336	5.5	21
185	Inhibition of Acinetobacter-Derived Cephalosporinase: Exploring the Carboxylate Recognition Site Using Novel Lactamase Inhibitors. <i>ACS Infectious Diseases</i> , <b>2018</b> , 4, 337-348	5.5	21

184	2267. The Effect of Opportunistic Infection (OI) Prophylaxis on the Gastrointestinal Microbiome (GIM) and Immune Reconstitution (IR) in Veterans With HIV and AIDS. <i>Open Forum Infectious Diseases</i> , <b>2018</b> , 5, S671-S671	1	78
183	698. Nacubactam Inhibits Class A Elactamases. <i>Open Forum Infectious Diseases</i> , <b>2018</b> , 5, S251-S252	1	78
182	2336. Resistance Mechanisms and Factors Associated With CTX-M-9 Group Extended-Spectrum Lactamase (ESBL)-Producing Enterobacteriaceae Infections in Children. <i>Open Forum Infectious Diseases</i> , <b>2018</b> , 5, S694-S694	1	78
181	700. Identification and Whole-Genome Sequencing (WGS) of Meropenem-Vaborbactam (MV) Resistant Klebsiella pneumoniae (MVRKP) Among Patients Without Prior Exposure to MV: Collateral Damage. <i>Open Forum Infectious Diseases</i> , <b>2018</b> , 5, S252-S252	1	78
180	2385. CeftazidimeAvibactam in Combination With Fosfomycin: A Novel Therapeutic Strategy Against Multidrug-Resistant Pseudomonas aeruginosa. <i>Open Forum Infectious Diseases</i> , <b>2018</b> , 5, S711-S7	' <del>1</del> 1	1
179	Deciphering the Evolution of Cephalosporin Resistance to Ceftolozane-Tazobactam in Pseudomonas aeruginosa. <i>MBio</i> , <b>2018</b> , 9,	7.8	42
178	Human serum albumin alters specific genes that can play a role in survival and persistence in Acinetobacter baumannii. <i>Scientific Reports</i> , <b>2018</b> , 8, 14741	4.9	21
177	Epidemiology of Carbapenem-Resistant Enterobacteriaceae at a Long-term Acute Care Hospital.  Open Forum Infectious Diseases, 2018, 5, ofy224	1	6
176	Defining the architecture of KPC-2 Carbapenemase: identifying allosteric networks to fight antibiotics resistance. <i>Scientific Reports</i> , <b>2018</b> , 8, 12916	4.9	19
175	Emergence of Resistance to Colistin During the Treatment of Bloodstream Infection Caused by Carbapenemase-Producing. <i>Open Forum Infectious Diseases</i> , <b>2018</b> , 5, ofy054	1	7
174	Development and validation of the INCREMENT-ESBL predictive score for mortality in patients with bloodstream infections due to extended-spectrum-flactamase-producing Enterobacteriaceae. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2017</b> , 72, 906-913	5.1	36
173	Transcriptome Remodeling of during Infection and Treatment. <i>MBio</i> , <b>2017</b> , 8,	7.8	23
172	Can Ceftazidime-Avibactam and Aztreonam Overcome Lactam Resistance Conferred by Metallo-Lactamases in Enterobacteriaceae?. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2017</b> , 61,	5.9	143
171	Overcoming an Extremely Drug Resistant (XDR) Pathogen: Avibactam Restores Susceptibility to Ceftazidime for Burkholderia cepacia Complex Isolates from Cystic Fibrosis Patients. <i>ACS Infectious Diseases</i> , <b>2017</b> , 3, 502-511	5.5	50
170	Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. Lancet Infectious Diseases, The, <b>2017</b> , 17, 726-734	25.5	268
169	The ecology of extended-spectrum Elactamases (ESBLs) in the developed world. <i>Journal of Travel Medicine</i> , <b>2017</b> , 24, S44-S51	12.9	110
168	Simple Screening for Carbapenemase-Producing Enterobacteriaceae by Moxalactam Susceptibility Testing. <i>Journal of Clinical Microbiology</i> , <b>2017</b> , 55, 2276-2279	9.7	2
167	Advancing Diagnostics to Address Antibacterial Resistance: The Diagnostics and Devices Committee of the Antibacterial Resistance Leadership Group. <i>Clinical Infectious Diseases</i> , <b>2017</b> , 64, S41-5	S476	19

166	Gram-Negative Bacterial Infections: Research Priorities, Accomplishments, and Future Directions of the Antibacterial Resistance Leadership Group. <i>Clinical Infectious Diseases</i> , <b>2017</b> , 64, S30-S35	11.6	78
165	A cold hard menace: A contaminated ice machine as a potential source for transmission of carbapenem-resistant Acinetobacter baumannii. <i>American Journal of Infection Control</i> , <b>2017</b> , 45, 1273-1	12378	6
164	Exploring the Landscape of Diazabicyclooctane (DBO) Inhibition: Avibactam Inactivation of PER-2 Lactamase. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2017</b> , 61,	5.9	11
163	WCK 5107 (Zidebactam) and WCK 5153 Are Novel Inhibitors of PBP2 Showing Potent "Lactam Enhancer" Activity against Pseudomonas aeruginosa, Including Multidrug-Resistant Metallo-Lactamase-Producing High-Risk Clones. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2017</b> ,	5.9	68
162	Exploring the potential of boronic acids as inhibitors of OXA-24/40 Elactamase. <i>Protein Science</i> , <b>2017</b> , 26, 515-526	6.3	24
161	Clinical and Pathophysiological Overview of Acinetobacter Infections: a Century of Challenges. <i>Clinical Microbiology Reviews</i> , <b>2017</b> , 30, 409-447	34	441
160	Influence of Aging and Environment on Presentation of Infection in Older Adults. <i>Infectious Disease Clinics of North America</i> , <b>2017</b> , 31, 593-608	6.5	34
159	Clinical Variants of New Delhi Metallo-Lactamase Are Evolving To Overcome Zinc Scarcity. <i>ACS Infectious Diseases</i> , <b>2017</b> , 3, 927-940	5.5	39
158	Carbapenemase-2 (KPC-2), Substitutions at Ambler Position Asp179, and Resistance to Ceftazidime-Avibactam: Unique Antibiotic-Resistant Phenotypes Emerge from Lactamase Protein Engineering. <i>MBio</i> , <b>2017</b> , 8,	7.8	68
157	Combination therapy for bloodstream infections with carbapenemase-producing Enterobacteriaceae - AuthorsRreply. <i>Lancet Infectious Diseases, The</i> , <b>2017</b> , 17, 1020-1021	25.5	4
156	An Analysis of the Epidemic of Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae: Convergence of Two Evolutionary Mechanisms Creates the "Perfect Storm". <i>Journal of Infectious Diseases</i> , <b>2017</b> , 217, 82-92	7	38
155	Diabetes Exacerbates Infection via Hyperinflammation by Signaling through TLR4 and RAGE. <i>MBio</i> , <b>2017</b> , 8,	7.8	37
154	Nosocomial Outbreak of Extensively Drug-Resistant Acinetobacter baumannii Isolates Containing Carried on a Plasmid. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2017</b> , 61,	5.9	24
153	A general reaction mechanism for carbapenem hydrolysis by mononuclear and binuclear metallo-Elactamases. <i>Nature Communications</i> , <b>2017</b> , 8, 538	17.4	68
152	Failure to Communicate: Transmission of Extensively Drug-Resistant bla OXA-237-Containing Acinetobacter baumannii-Multiple Facilities in Oregon, 2012-2014. <i>Infection Control and Hospital Epidemiology</i> , <b>2017</b> , 38, 1335-1341	2	11
151	Avibactam Restores the Susceptibility of Clinical Isolates of Stenotrophomonas maltophilia to Aztreonam. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2017</b> , 61,	5.9	36
150	Dipicolinic Acid Derivatives as Inhibitors of New Delhi Metallo-Elactamase-1. <i>Journal of Medicinal Chemistry</i> , <b>2017</b> , 60, 7267-7283	8.3	94
149	A 17-Year Nationwide Study of Burkholderia cepacia Complex Bloodstream Infections Among Patients in the United States Veterans Health Administration. <i>Clinical Infectious Diseases.</i> <b>2017</b> . 65. 125	3 <sup>11</sup> 26 3-1259	17

148	Monoclonal Antibody Protects Against Acinetobacter baumannii Infection by Enhancing Bacterial Clearance and Evading Sepsis. <i>Journal of Infectious Diseases</i> , <b>2017</b> , 216, 489-501	7	38
147	Informing Antibiotic Treatment Decisions: Evaluating Rapid Molecular Diagnostics To Identify Susceptibility and Resistance to Carbapenems against Acinetobacter spp. in PRIMERS III. <i>Journal of Clinical Microbiology</i> , <b>2017</b> , 55, 134-144	9.7	22
146	Lactamases: A Focus on Current Challenges. Cold Spring Harbor Perspectives in Medicine, 2017, 7,	5.4	122
145	Empiric Therapy With Carbapenem-Sparing Regimens for Bloodstream Infections due to Extended-Spectrum Lactamase-Producing Enterobacteriaceae: Results From the INCREMENT Cohort. Clinical Infectious Diseases, 2017, 65, 1615-1623	11.6	33
144	A Prospective Observational Study of the Epidemiology, Management, and Outcomes of Skin and Soft Tissue Infections Due to Carbapenem-Resistant. <i>Open Forum Infectious Diseases</i> , <b>2017</b> , 4, ofx157	1	18
143	A Comparison of Molecular Typing Methods Applied to Enterobacter cloacae complex: hsp60 Sequencing, Rep-PCR, and MLST. <i>Pathogens and Immunity</i> , <b>2017</b> , 2, 23	4.9	5
142	Colistin Resistance in Carbapenem-Resistant Klebsiella pneumoniae: Laboratory Detection and Impact on Mortality. <i>Clinical Infectious Diseases</i> , <b>2017</b> , 64, 711-718	11.6	100
141	Successful Treatment of Bloodstream Infection Due to Metallo-Lactamase-Producing Stenotrophomonas maltophilia in a Renal Transplant Patient. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2016</b> , 60, 5130-4	5.9	43
140	Ceftazidime-Avibactam for the Treatment of Post-Neurosurgical Meningitis Caused by a Klebsiella pneumoniae carbapenemase (KPC)-Producing Klebsiella pneumoniae. <i>Open Forum Infectious Diseases</i> , <b>2016</b> , 3,	1	9
139	Reply to Lesho and Clifford. <i>Clinical Infectious Diseases</i> , <b>2016</b> , 63, 571-2	11.6	1
139	Reply to Lesho and Clifford. <i>Clinical Infectious Diseases</i> , <b>2016</b> , 63, 571-2  Whole-Genome Comparative Analysis of Two Carbapenem-Resistant ST-258 Klebsiella pneumoniae Strains Isolated during a North-Eastern Ohio Outbreak: Differences within the High Heterogeneity Zones. <i>Genome Biology and Evolution</i> , <b>2016</b> , 8, 2036-43	3.9	1 22
	Whole-Genome Comparative Analysis of Two Carbapenem-Resistant ST-258 Klebsiella pneumoniae Strains Isolated during a North-Eastern Ohio Outbreak: Differences within the High Heterogeneity		22
138	Whole-Genome Comparative Analysis of Two Carbapenem-Resistant ST-258 Klebsiella pneumoniae Strains Isolated during a North-Eastern Ohio Outbreak: Differences within the High Heterogeneity Zones. <i>Genome Biology and Evolution</i> , <b>2016</b> , 8, 2036-43  Cross-class metallo-Eactamase inhibition by bisthiazolidines reveals multiple binding modes.	3.9	22
138	Whole-Genome Comparative Analysis of Two Carbapenem-Resistant ST-258 Klebsiella pneumoniae Strains Isolated during a North-Eastern Ohio Outbreak: Differences within the High Heterogeneity Zones. <i>Genome Biology and Evolution</i> , <b>2016</b> , 8, 2036-43  Cross-class metallo-Elactamase inhibition by bisthiazolidines reveals multiple binding modes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2016</b> , 113, E3745-54  Risk Factors and Outcomes for Carbapenem-Resistant Klebsiella pneumoniae Isolation, Stratified by Its Multilocus Sequence Typing: ST258 Versus Non-ST258. <i>Open Forum Infectious Diseases</i> , <b>2016</b> ,	3.9	22
138 137 136	Whole-Genome Comparative Analysis of Two Carbapenem-Resistant ST-258 Klebsiella pneumoniae Strains Isolated during a North-Eastern Ohio Outbreak: Differences within the High Heterogeneity Zones. <i>Genome Biology and Evolution</i> , <b>2016</b> , 8, 2036-43  Cross-class metallo-Elactamase inhibition by bisthiazolidines reveals multiple binding modes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2016</b> , 113, E3745-54  Risk Factors and Outcomes for Carbapenem-Resistant Klebsiella pneumoniae Isolation, Stratified by Its Multilocus Sequence Typing: ST258 Versus Non-ST258. <i>Open Forum Infectious Diseases</i> , <b>2016</b> , 3, ofv213  Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study. <i>Journal of Antimicrobial</i>	3.9 11.5	22 87 11
138 137 136	Whole-Genome Comparative Analysis of Two Carbapenem-Resistant ST-258 Klebsiella pneumoniae Strains Isolated during a North-Eastern Ohio Outbreak: Differences within the High Heterogeneity Zones. <i>Genome Biology and Evolution</i> , <b>2016</b> , 8, 2036-43  Cross-class metallo-Elactamase inhibition by bisthiazolidines reveals multiple binding modes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2016</b> , 113, E3745-54  Risk Factors and Outcomes for Carbapenem-Resistant Klebsiella pneumoniae Isolation, Stratified by Its Multilocus Sequence Typing: ST258 Versus Non-ST258. <i>Open Forum Infectious Diseases</i> , <b>2016</b> , 3, ofv213  Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2016</b> , 71, 1672-80  Genome dynamics of multidrug-resistant Acinetobacter baumannii during infection and treatment.	3.9 11.5 1 5.1	22 87 11
138 137 136 135	Whole-Genome Comparative Analysis of Two Carbapenem-Resistant ST-258 Klebsiella pneumoniae Strains Isolated during a North-Eastern Ohio Outbreak: Differences within the High Heterogeneity Zones. <i>Genome Biology and Evolution</i> , <b>2016</b> , 8, 2036-43  Cross-class metallo-Elactamase inhibition by bisthiazolidines reveals multiple binding modes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2016</b> , 113, E3745-54  Risk Factors and Outcomes for Carbapenem-Resistant Klebsiella pneumoniae Isolation, Stratified by Its Multilocus Sequence Typing: ST258 Versus Non-ST258. <i>Open Forum Infectious Diseases</i> , <b>2016</b> , 3, ofv213  Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2016</b> , 71, 1672-80  Genome dynamics of multidrug-resistant Acinetobacter baumannii during infection and treatment. <i>Genome Medicine</i> , <b>2016</b> , 8, 26  Boronic Acid Transition State Inhibitors Active against KPC and Other Class A Elactamases: Structure-Activity Relationships as a Guide to Inhibitor Design. <i>Antimicrobial Agents and</i>	3.9 11.5 1 5.1 14.4	22 87 11 33 48

130	Exposing a Lactamase "Twist": the Mechanistic Basis for the High Level of Ceftazidime Resistance in the C69F Variant of the Burkholderia pseudomallei PenI Lactamase. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2016</b> , 60, 777-88	5.9	18
129	Rapid Molecular Diagnostics, Antibiotic Treatment Decisions, and Developing Approaches to Inform Empiric Therapy: PRIMERS I and II. <i>Clinical Infectious Diseases</i> , <b>2016</b> , 62, 181-9	11.6	44
128	Intestinal Carriage of Carbapenemase-Producing Organisms: Current Status of Surveillance Methods. <i>Clinical Microbiology Reviews</i> , <b>2016</b> , 29, 1-27	34	112
127	B1-Metallo-Lactamases: Where Do We Stand?. Current Drug Targets, 2016, 17, 1029-50	3	113
126	Multidrug Resistant Causing Prosthetic Valve Endocarditis: A Genetic-Based Chronicle of Evolving Antibiotic Resistance. <i>Open Forum Infectious Diseases</i> , <b>2016</b> , 3, ofw188	1	17
125	Ceftazidime/Avibactam and Ceftolozane/Tazobactam in Treatment of Pulmonary Infections by Imipenem Resistant Pseudomonas aeruginosa. <i>Open Forum Infectious Diseases</i> , <b>2016</b> , 3,	1	1
124	Application of "Precision Medicine" Through the Molecular Characterization of Extensively Drug Resistant (XDR) Klebsiella pneumoniae in a Multivisceral Transplant Candidate. <i>Open Forum Infectious Diseases</i> , <b>2016</b> , 3,	1	1
123	Prosthetic Valve Endocarditis Caused by : A Case Report of Molecular Diagnostics Informing Nonsurgical Management. <i>Open Forum Infectious Diseases</i> , <b>2016</b> , 3, ofw202	1	2
122	Prosthetic Valve Endocarditis (PVE) Caused by Bartonella henselae: A Case Report of Molecular Methods to Diagnose and Inform Non-Surgical Management. <i>Open Forum Infectious Diseases</i> , <b>2016</b> , 3,	1	1
121	Bacterial Colonization and Antibiotic Resistance in a Prospective Cohort of Newborn Infants During the First Year of Life. <i>Open Forum Infectious Diseases</i> , <b>2016</b> , 3, ofw221	1	5
120	Analysis of £Lactamase Resistance Determinants in Enterobacteriaceae from Chicago Children: a Multicenter Survey. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2016</b> , 60, 3462-9	5.9	25
119	Benefit-risk Evaluation for Diagnostics: A Framework (BED-FRAME). <i>Clinical Infectious Diseases</i> , <b>2016</b> , 63, 812-7	11.6	18
118	Overview: Global and Local Impact of Antibiotic Resistance. <i>Infectious Disease Clinics of North America</i> , <b>2016</b> , 30, 313-322	6.5	112
117	New £Lactamase Inhibitors in the Clinic. <i>Infectious Disease Clinics of North America</i> , <b>2016</b> , 30, 441-464	6.5	109
116	Membrane anchoring stabilizes and favors secretion of New Delhi metallo-Elactamase. <i>Nature Chemical Biology</i> , <b>2016</b> , 12, 516-22	11.7	81
115	Initial Assessment of the Molecular Epidemiology of blaNDM-1 in Colombia. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2016</b> , 60, 4346-50	5.9	18
114	Mutations Decreasing Intrinsic Lactam Resistance Are Linked to Cell Division in the Nosocomial Pathogen Acinetobacter baumannii. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2016</b> , 60, 3751-8	5.9	13
113	Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation £Lactam/£Lactamase Inhibitor Combinations. <i>Clinical Infectious Diseases</i> , <b>2016</b> , 63, 234-41	11.6	322

112	LN-1-255, a penicillanic acid sulfone able to inhibit the class D carbapenemase OXA-48. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2016</b> , 71, 2171-80	5.1	19
111	A Multinational, Preregistered Cohort Study of Lactam/Lactamase Inhibitor Combinations for Treatment of Bloodstream Infections Due to Extended-Spectrum-Lactamase-Producing Enterobacteriaceae. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2016</b> , 60, 4159-69	5.9	96
110	First Report of a Verona Integron-Encoded Metallo-Lactamase-Producing Klebsiella pneumoniae Infection in a Child in the United States. <i>Journal of the Pediatric Infectious Diseases Society</i> , <b>2016</b> , 5, e24	1-7 <sup>4.8</sup>	4
109	Molecular Diversity and Plasmid Analysis of KPC-Producing Escherichia coli. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2016</b> , 60, 4073-81	5.9	27
108	A Predictive Model of Mortality in Patients With Bloodstream Infections due to Carbapenemase-Producing Enterobacteriaceae. <i>Mayo Clinic Proceedings</i> , <b>2016</b> , 91, 1362-1371	6.4	66
107	Activities of ceftazidime, ceftaroline, and aztreonam alone and combined with avibactam against isogenic Escherichia coli strains expressing selected single Elactamases. <i>Diagnostic Microbiology and Infectious Disease</i> , <b>2015</b> , 82, 65-9	2.9	37
106	Complete sequence of a bla(KPC)-harboring cointegrate plasmid isolated from Escherichia coli. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2015</b> , 59, 2956-9	5.9	16
105	Community-Acquired Pyelonephritis in Pregnancy Caused by KPC-Producing Klebsiella pneumoniae. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2015</b> , 59, 4375-8	5.9	14
104	Bisthiazolidines: A Substrate-Mimicking Scaffold as an Inhibitor of the NDM-1 Carbapenemase. <i>ACS Infectious Diseases</i> , <b>2015</b> , 1, 544-54	5.5	78
103	Click Chemistry in Lead Optimization of Boronic Acids as £Lactamase Inhibitors. <i>Journal of Medicinal Chemistry</i> , <b>2015</b> , 58, 5445-58	8.3	31
102	Contamination of Ambient Air with Acinetobacter baumannii on Consecutive Inpatient Days. <i>Journal of Clinical Microbiology</i> , <b>2015</b> , 53, 2346-8	9.7	15
101	Structural basis of activity against aztreonam and extended spectrum cephalosporins for two carbapenem-hydrolyzing class D Elactamases from Acinetobacter baumannii. <i>Biochemistry</i> , <b>2015</b> , 54, 1976-87	3.2	21
100	First report of an OXA-48-producing multidrug-resistant Proteus mirabilis strain from Gaza, Palestine. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2015</b> , 59, 4305-7	5.9	32
99	SISPA-Seq for rapid whole genome surveys of bacterial isolates. <i>Infection, Genetics and Evolution</i> , <b>2015</b> , 32, 191-8	4.5	10
98	Predominance of KPC-3 in a survey for carbapenemase-producing Enterobacteriaceae in Portugal. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2015</b> , 59, 3588-92	5.9	34
97	Activity of ceftazidime/avibactam against isogenic strains of Escherichia coli containing KPC and SHV Elactamases with single amino acid substitutions in the Eloop. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2015</b> , 70, 2279-86	5.1	73
96	In Vivo Evolution of CMY-2 to CMY-33 Lactamase in Escherichia coli Sequence Type 131: Characterization of an Acquired Extended-Spectrum AmpC Conferring Resistance to Cefepime. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2015</b> , 59, 7483-8	5.9	13
95	ESBLs: An emerging problem in pediatric infectious diseases. <i>Journal of Pediatric Infectious Diseases</i> , <b>2015</b> , 03, 217-220	0.4	1

94	Performance of the CLSI Carba NP and the Rosco Carb Screen Assays Using North American Carbapenemase-Producing Enterobacteriaceae and Pseudomonas aeruginosa Isolates. <i>Journal of Clinical Microbiology</i> , <b>2015</b> , 53, 3370-3	9.7	13
93	Elucidating the Role of Residue 67 in IMP-Type Metallo-Lactamase Evolution. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2015</b> , 59, 7299-307	5.9	17
92	Unexpected challenges in treating multidrug-resistant Gram-negative bacteria: resistance to ceftazidime-avibactam in archived isolates of Pseudomonas aeruginosa. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2015</b> , 59, 1020-9	5.9	104
91	Genomic and transcriptomic analyses of colistin-resistant clinical isolates of Klebsiella pneumoniae reveal multiple pathways of resistance. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2015</b> , 59, 536-43	5.9	131
90	Membrane-Bound PenA Lactamase of Burkholderia pseudomallei. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2015</b> , 60, 1509-14	5.9	17
89	Host fate is rapidly determined by innate effector-microbial interactions during Acinetobacter baumannii bacteremia. <i>Journal of Infectious Diseases</i> , <b>2015</b> , 211, 1296-305	7	55
88	External guide sequence technology: a path to development of novel antimicrobial therapeutics. <i>Annals of the New York Academy of Sciences</i> , <b>2015</b> , 1354, 98-110	6.5	24
87	Steering Evolution with Sequential Therapy to Prevent the Emergence of Bacterial Antibiotic Resistance. <i>PLoS Computational Biology</i> , <b>2015</b> , 11, e1004493	5	93
86	Inhibition of Klebsiella £Lactamases (SHV-1 and KPC-2) by Avibactam: A Structural Study. <i>PLoS ONE</i> , <b>2015</b> , 10, e0136813	3.7	47
85	Immunomodulatory Peptide IDR-1018 Decreases Implant Infection and Preserves Osseointegration. <i>Clinical Orthopaedics and Related Research</i> , <b>2015</b> , 473, 2898-907	2.2	28
84	Are Staphylococcus intermedius Infections in Humans Cases of Mistaken Identity? A Case Series and Literature Review. <i>Open Forum Infectious Diseases</i> , <b>2015</b> , 2, ofv110	1	14
83	Avibactam and inhibitor-resistant SHV Elactamases. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2015</b> , 59, 3700-9	5.9	56
82	Variants of Elactamase KPC-2 that are resistant to inhibition by avibactam. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2015</b> , 59, 3710-7	5.9	72
81	Impact of therapy and strain type on outcomes in urinary tract infections caused by carbapenem-resistant Klebsiella pneumoniae. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2015</b> , 70, 1203-11	5.1	39
80	The different inhibition mechanisms of OXA-1 and OXA-24 Elactamases are determined by the stability of active site carboxylated lysine. <i>Journal of Biological Chemistry</i> , <b>2014</b> , 289, 6152-64	5.4	16
79	Molecular dissection of the evolution of carbapenem-resistant multilocus sequence type 258 Klebsiella pneumoniae. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2014</b> , 111, 4988-93	11.5	230
78	Outcomes of carbapenem-resistant Enterobacteriaceae isolation: matched analysis. <i>American Journal of Infection Control</i> , <b>2014</b> , 42, 612-20	3.8	34
77	New Elactamase inhibitors: a therapeutic renaissance in an MDR world. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2014</b> , 58, 1835-46	5.9	227

76	Biochemical, mechanistic, and spectroscopic characterization of metallo-Elactamase VIM-2. <i>Biochemistry</i> , <b>2014</b> , 53, 7321-31	3.2	47
75	Antibiotic-resistant gram-negative bacterial infections in patients with cancer. <i>Clinical Infectious Diseases</i> , <b>2014</b> , 59 Suppl 5, S335-9	11.6	70
74	Surveillance of carbapenem-resistant Klebsiella pneumoniae: tracking molecular epidemiology and outcomes through a regional network. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2014</b> , 58, 4035-41	5.9	100
73	Epithelial innate immune response to Acinetobacter baumannii challenge. <i>Infection and Immunity</i> , <b>2014</b> , 82, 4458-65	3.7	18
72	A fluorescent carbapenem for structure function studies of penicillin-binding proteins, Elactamases, and Elactam sensors. <i>Analytical Biochemistry</i> , <b>2014</b> , 463, 70-4	3.1	16
71	Identification of occult Fusobacterium nucleatum central nervous system infection by use of PCR-electrospray ionization mass spectrometry. <i>Journal of Clinical Microbiology</i> , <b>2014</b> , 52, 3462-4	9.7	6
70	Extensively drug-resistant pseudomonas aeruginosa isolates containing blaVIM-2 and elements of Salmonella genomic island 2: a new genetic resistance determinant in Northeast Ohio. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2014</b> , 58, 5929-35	5.9	28
69	Carbapenemase-producing Klebsiella pneumoniae: molecular and genetic decoding. <i>Trends in Microbiology</i> , <b>2014</b> , 22, 686-96	12.4	281
68	Reclaiming the efficacy of Elactam-Elactamase inhibitor combinations: avibactam restores the susceptibility of CMY-2-producing Escherichia coli to ceftazidime. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2014</b> , 58, 4290-7	5.9	32
67	New insights into dissemination and variation of the health care-associated pathogen Acinetobacter baumannii from genomic analysis. <i>MBio</i> , <b>2014</b> , 5, e00963-13	7.8	124
66	Crystal structure of Mox-1, a unique plasmid-mediated class C Elactamase with hydrolytic activity towards moxalactam. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2014</b> , 58, 3914-20	5.9	7
65	Multiplex PCR for identification of two capsular types in epidemic KPC-producing Klebsiella pneumoniae sequence type 258 strains. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2014</b> , 58, 4196-9	5.9	22
64	Ureaplasma parvum prosthetic joint infection detected by PCR. <i>Journal of Clinical Microbiology</i> , <b>2014</b> , 52, 2248-50	9.7	15
63	Direct detection of indirect transmission of Streptobacillus moniliformis rat bite fever infection. Journal of Clinical Microbiology, <b>2014</b> , 52, 2259-61	9.7	10
62	Infections caused by fluoroquinolone-resistant following transrectal ultrasound-guided biopsy of the prostate. <i>Journal of Global Antimicrobial Resistance</i> , <b>2014</b> , 2, 71-76	3.4	9
61	Penam sulfones and Elactamase inhibition: SA2-13 and the importance of the C2 side chain length and composition. <i>PLoS ONE</i> , <b>2014</b> , 9, e85892	3.7	8
60	960The Molecular Characterization of Extended-Spectrum Beta-Lactamase (ESBL) and Carbapenem- Resistant Enterobacteriaceae (CRE) in Chicago Children, a two center study. <i>Open Forum Infectious Diseases</i> , <b>2014</b> , 1, S279-S280	1	
59	Culture negative empyema in a critically ill child: an opportunity for rapid molecular diagnostics. <i>BMC Anesthesiology</i> , <b>2014</b> , 14, 107	2.4	2

58	Erratum for Wright et al., Population Structure of KPC-Producing Klebsiella pneumoniae Isolates from Midwestern U.S. Hospitals. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2014</b> , 58, 6343-6343	5.9	78
57	Host-specific enzyme-substrate interactions in SPM-1 metallo-lactamase are modulated by second sphere residues. <i>PLoS Pathogens</i> , <b>2014</b> , 10, e1003817	7.6	26
56	Genome Sequences of Two Carbapenemase-Resistant Klebsiella pneumoniae ST258 Isolates. <i>Genome Announcements</i> , <b>2014</b> , 2,		8
55	Population structure of KPC-producing Klebsiella pneumoniae isolates from midwestern U.S. hospitals. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2014</b> , 58, 4961-5	5.9	61
54	Biochemical and structural analysis of inhibitors targeting the ADC-7 cephalosporinase of Acinetobacter baumannii. <i>Biochemistry</i> , <b>2014</b> , 53, 7670-9	3.2	23
53	Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. <i>Lancet Infectious Diseases, The</i> , <b>2013</b> , 13, 785-96	25.5	1030
52	Non-phenotypic tests to detect and characterize antibiotic resistance mechanisms in Enterobacteriaceae. <i>Diagnostic Microbiology and Infectious Disease</i> , <b>2013</b> , 77, 179-94	2.9	61
51	Acinetobacter baumannii rOmpA vaccine dose alters immune polarization and immunodominant epitopes. <i>Vaccine</i> , <b>2013</b> , 31, 313-8	4.1	50
50	First clinical cases of OXA-48-producing carbapenem-resistant Klebsiella pneumoniae in the United States: the "menace" arrives in the new world. <i>Journal of Clinical Microbiology</i> , <b>2013</b> , 51, 680-3	9.7	80
49	Insights into Elactamases from Burkholderia species, two phylogenetically related yet distinct resistance determinants. <i>Journal of Biological Chemistry</i> , <b>2013</b> , 288, 19090-102	5.4	40
48	"Stormy waters ahead": global emergence of carbapenemases. Frontiers in Microbiology, 2013, 4, 48	5.7	280
47	Draft Genome Sequence of the Clinical Isolate Acinetobacter nosocomialis Strain M2. <i>Genome Announcements</i> , <b>2013</b> , 1,		26
46	Novel Elactamase inhibitors: a therapeutic hope against the scourge of multidrug resistance. <i>Frontiers in Microbiology</i> , <b>2013</b> , 4, 392	5.7	46
45	Detection of extended-spectrum Elactamase and Klebsiella pneumoniae Carbapenemase genes directly from blood cultures by use of a nucleic acid microarray. <i>Journal of Clinical Microbiology</i> , <b>2012</b> , 50, 2901-4	9.7	22
44	"Silent" dissemination of Klebsiella pneumoniae isolates bearing K. pneumoniae carbapenemase in a long-term care facility for children and young adults in Northeast Ohio. <i>Clinical Infectious Diseases</i> , <b>2012</b> , 54, 1314-21	11.6	65
43	Understanding the molecular determinants of substrate and inhibitor specificities in the Carbapenemase KPC-2: exploring the roles of Arg220 and Glu276. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2012</b> , 56, 4428-38	5.9	37
42	Exploring the role of a conserved class A residue in the £Loop of KPC-2 £Lactamase: a mechanism for ceftazidime hydrolysis. <i>Journal of Biological Chemistry</i> , <b>2012</b> , 287, 31783-93	5.4	57
41	Crystal structures of KPC-2 Elactamase in complex with 3-nitrophenyl boronic acid and the penam sulfone PSR-3-226. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2012</b> , 56, 2713-8	5.9	33

# (2010-2012)

40	Inhibition of LpxC protects mice from resistant Acinetobacter baumannii by modulating inflammation and enhancing phagocytosis. <i>MBio</i> , <b>2012</b> , 3,	7.8	99
39	Early insights into the interactions of different Elactam antibiotics and Elactamase inhibitors against soluble forms of Acinetobacter baumannii PBP1a and Acinetobacter sp. PBP3. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2012</b> , 56, 5687-92	5.9	23
38	Active and passive immunization protects against lethal, extreme drug resistant-Acinetobacter baumannii infection. <i>PLoS ONE</i> , <b>2012</b> , 7, e29446	3.7	106
37	Carbapenems: past, present, and future. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2011</b> , 55, 4943-60	5.9	75 <sup>2</sup>
36	Exploring sequence requirements for CICL arboxylate recognition in the Pseudomonas aeruginosa cephalosporinase: Insights into plasticity of the AmpC Elactamase. <i>Protein Science</i> , <b>2011</b> , 20, 941-58	6.3	34
35	Ligand-dependent disorder of the Omega loop observed in extended-spectrum SHV-type beta-lactamase. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2011</b> , 55, 2303-9	5.9	17
34	Extended-spectrum AmpC cephalosporinase in Acinetobacter baumannii: ADC-56 confers resistance to cefepime. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2011</b> , 55, 4922-5	5.9	48
33	Increasing prevalence and dissemination of NDM-1 metallo-lactamase in India: data from the SMART study (2009). <i>Journal of Antimicrobial Chemotherapy</i> , <b>2011</b> , 66, 1992-7	5.1	133
32	Evaluation of updated interpretative criteria for categorizing Klebsiella pneumoniae with reduced carbapenem susceptibility. <i>Journal of Clinical Microbiology</i> , <b>2010</b> , 48, 4417-25	9.7	43
31	Inhibitor resistance in the KPC-2 beta-lactamase, a preeminent property of this class A beta-lactamase. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2010</b> , 54, 890-7	5.9	132
30	Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2010</b> , 54, 2867-77	5.9	44
29	Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2010</b> , 54, 4201-7	5.9	118
28	Carbapenem-resistant Acinetobacter baumannii and Klebsiella pneumoniae across a hospital system: impact of post-acute care facilities on dissemination. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2010</b> , 65, 1807-18	5.1	147
27	Penicillin sulfone inhibitors of class D beta-lactamases. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2010</b> , 54, 1414-24	5.9	36
26	Inhibition of the class C beta-lactamase from Acinetobacter spp.: insights into effective inhibitor design. <i>Biochemistry</i> , <b>2010</b> , 49, 329-40	3.2	36
25	Design, synthesis, and crystal structures of 6-alkylidene-2Rsubstituted penicillanic acid sulfones as potent inhibitors of Acinetobacter baumannii OXA-24 carbapenemase. <i>Journal of the American Chemical Society</i> , <b>2010</b> , 132, 13320-31	16.4	50
24	Three decades of beta-lactamase inhibitors. Clinical Microbiology Reviews, 2010, 23, 160-201	34	1115
23	Elucidating the role of Trp105 in the KPC-2 Elactamase. <i>Protein Science</i> , <b>2010</b> , 19, 1714-27	6.3	44

22	Characterization of blaKPC-containing Klebsiella pneumoniae isolates detected in different institutions in the Eastern USA. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2009</b> , 63, 427-37	5.1	176
21	Identification of plasmid-mediated AmpC beta-lactamases in Escherichia coli, Klebsiella spp., and proteus species can potentially improve reporting of cephalosporin susceptibility testing results. Journal of Clinical Microbiology, <b>2009</b> , 47, 294-9	9.7	32
20	Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2009</b> , 53, 3628-34	5.9	322
19	Performance of the Phoenix bacterial identification system compared with disc diffusion methods for identifying extended-spectrum beta-lactamase, AmpC and KPC producers. <i>Journal of Medical Microbiology</i> , <b>2009</b> , 58, 774-778	3.2	16
18	Inhibition of OXA-1 beta-lactamase by penems. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2008</b> , 52, 3135-	- <b>43</b> 9	32
17	Comparative genome sequence analysis of multidrug-resistant Acinetobacter baumannii. <i>Journal of Bacteriology</i> , <b>2008</b> , 190, 8053-64	3.5	348
16	Inhibition of class A beta-lactamases by carbapenems: crystallographic observation of two conformations of meropenem in SHV-1. <i>Journal of the American Chemical Society</i> , <b>2008</b> , 130, 12656-62	16.4	58
15	Isolation and characterization of an autoinducer synthase from Acinetobacter baumannii. <i>Journal of Bacteriology</i> , <b>2008</b> , 190, 3386-92	3.5	193
14	The role of OXA-1 beta-lactamase Asp(66) in the stabilization of the active-site carbamate group and in substrate turnover. <i>Biochemical Journal</i> , <b>2008</b> , 410, 455-62	3.8	21
13	Crystal structure of KPC-2: insights into carbapenemase activity in class A beta-lactamases. <i>Biochemistry</i> , <b>2007</b> , 46, 5732-40	3.2	82
12	Topical triple-antibiotic ointment as a novel therapeutic choice in wound management and infection prevention: a practical perspective. <i>Expert Review of Anti-Infective Therapy</i> , <b>2007</b> , 5, 773-82	5.5	19
11	Global challenge of multidrug-resistant Acinetobacter baumannii. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2007</b> , 51, 3471-84	5.9	835
10	Role of Asp104 in the SHV beta-lactamase. Antimicrobial Agents and Chemotherapy, 2006, 50, 4124-31	5.9	25
9	Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. <i>Clinical Infectious Diseases</i> , <b>2006</b> , 43 Suppl 2, S49-56	11.6	453
8	Analysis of antibiotic resistance genes in multidrug-resistant Acinetobacter sp. isolates from military and civilian patients treated at the Walter Reed Army Medical Center. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2006</b> , 50, 4114-23	5.9	365
7	Multiple Substitutions at Ambler Position 244 in SHV Provide Insight Into Importance of Arg244 in Inhibitor and Substrate Binding. <i>FASEB Journal</i> , <b>2006</b> , 20, A896	0.9	
6	Identification of a new allelic variant of the Acinetobacter baumannii cephalosporinase, ADC-7 beta-lactamase: defining a unique family of class C enzymes. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2005</b> , 49, 2941-8	5.9	119
5	Ultrahigh resolution structure of a class A beta-lactamase: on the mechanism and specificity of the extended-spectrum SHV-2 enzyme. <i>Journal of Molecular Biology</i> , <b>2003</b> , 328, 289-301	6.5	110

#### LIST OF PUBLICATIONS

4	Resistant pathogens in respiratory tract infections in older people. <i>Journal of the American Geriatrics Society</i> , <b>2002</b> , 50, S236-41	5.6	14
3	Inactivation of CMY-2 beta-lactamase by tazobactam: initial mass spectroscopic characterization. <i>BBA - Proteins and Proteomics</i> , <b>2001</b> , 1547, 196-205		23
2	Kinetic analysis of an inhibitor-resistant variant of the OHIO-1 beta-lactamase, an SHV-family class A enzyme. <i>Biochemical Journal</i> , <b>1998</b> , 333 ( Pt 2), 395-400	3.8	29
1	Overview of Aminoglycosides and Enzyme-Mediated Bacterial Resistance, Clinical Implications1-6		